Evolus, Inc. (NASDAQ: EOLS) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT EVOLUS, INC.

Evolus, Inc. (NASDAQ: EOLS)
Listen to this Section


$6.42
-0.1850 ( -2.80% ) 153.3K

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Market Data


Open $6.42
Previous Close $6.60
Volume 153.3K
Market Cap $434.64M
Day Range $6.40 - $6.69
52 Week Range $3.86 - $10.62
Shares Outstanding 65.85M
Change % -2.80%
Net Change ▼ -0.1850
Insider Ownership 0.00%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2018
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -446,373.00

Date Type Amount Purchased Purchaser
2024-02-09 Sale -24648.00 Yamagishi-Dressler Tomoko
2024-02-09 Sale -35211.00 Beaver Sandra
2024-02-09 Sale -35211.00 Avelar Rui
2024-02-09 Sale -134976.00 MOATAZEDI DAVID
2024-02-02 Sale -11931.00 Parschauer Karah Herdman
2023-12-08 Sale -51348.00 MOATAZEDI DAVID

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 69 Nov 05, 2025
8-k 8K-related 14 Nov 05, 2025
3 Insider transactions 2 Oct 09, 2025
4 Insider transactions 1 Oct 09, 2025
8-k 8K-related 14 Sep 08, 2025
4 Insider transactions 1 Aug 26, 2025
4 Insider transactions 1 Aug 18, 2025
8-k 8K-related 14 Aug 05, 2025
10-q Quarterly Reports 71 Aug 05, 2025
4 Insider transactions 1 Jun 16, 2025

Latest News


× Before browsing our site, please accept our cookies policy